Skip to content

Experience sampling for detection of early clinical changes during dose reduction of antipsychotics in patients with a psychotic disorder

Experience sampling for detection of early clinical changes during dose reduction of antipsychotics in patients with a psychotic disorder - experience sampling during dose reduction of antipsychotics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON48652
Enrollment
30
Registered
2018-06-21
Start date
2019-03-04
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychotic disorder

Interventions

niet van toepassing

Sponsors

GGzE
Lead Sponsor

Eligibility

Age
16 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. The participant has a diagnosis of a psychotic disorder. 2. Psychotic symptoms are in remission for at least three months for first episode psychosis and at least six months for multiple episode psychosis. 3. Age 16-65 years. 4. The participant understands the study and is able to provide written informed consent. 5. The participant is not participating in a medication study. 6. The participant is currently using antipsychotic medication and participant and his/her treating clinician agree to discontinuation/dose reduction. Patients with depot medication can also participate. 7. Sufficient command of the Dutch language. 8. Sufficient vision to read the questions in the PsyMate app and sufficient hearing to hear the PsyMate signals.

Exclusion criteria

Exclusion criteria: Exclusion criteria are kept as few as possible. Only when the safety of the participant is at risk, exclusion will follow. Patients will be excluded from the trial if patients are not in remission (at least 3 months for first episode patients and at least 6 months for multiple episodes) .

Design outcomes

Primary

MeasureTime frame
Momentary mental states and behaviour in terms of psychotic experiences, subjective well-being (positive affect, negative affect, physical well-being), social interactions, sleep, cognition, dopamine super-sensitivity and negative symptoms in the context of daily life.

Secondary

MeasureTime frame
Clinical symptoms, mental health and functioning, recovery, physical complaints/side effects, quality of life

Countries

Netherlands

Contacts

Public ContactC. J. P. Simons

GGzE

claudia.simons@ggze.nlGGzE: +31-40-2970170

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 11, 2026